Open AccessOmalizumab for the treatment of severe allergic asthma in children: A tale of two
Author(s) -
Brannick Sinéad,
McDonald Mary,
Greally Peter,
Elnazir Basil,
Ahmareen Oneza
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.6255
Subject(s) - omalizumab , medicine , asthma , cohort , endotype , allergic asthma , pediatrics , mepolizumab , intensive care medicine , immunology , immunoglobulin e , antibody , eosinophil
Abstract Omalizumab is a monoclonal antibody which targets immunoglobulin E. It is approved as an add‐on therapy for children with severe allergic asthma. Assessment of endotype and phenotype is necessary in order to correctly identify those patients who are most likely to respond to omalizumab. Children with severe asthma represent a complex heterogeneous group. This report outlines the background, management, and outcomes for two children initiated on omalizumab for severe allergic asthma in Children's Health Ireland at Tallaght. It demonstrates the difficulties faced by this cohort and the positive impact targeted biological therapy can have. Given the substantial cohort of children with asthma attending our tertiary center, it also indicates that comprehensive stepwise care can achieve adequate control in the vast majority of cases without the requirement for additional therapies.